Alzheimer's & Dementia

Volume 5, Issue 4 p. 348-360

Review Article

Alzheimer's disease and infection: Do infectious agents contribute to progression of Alzheimer's disease?

Kie Honjo,

Kie Honjo

L.C. Campbell Cognitive Neurology Research Unit, Heart and Stroke Foundation Centre for Stroke Recovery, Section of Neurology, Department of Medicine, Sunnybrook Health Science Centre and University of Toronto, Toronto, Ontario, Canada

Kunin-Lunenfeld Applied Research Unit Baycrest, Toronto, Ontario, Canada

Search for more papers by this author

Robert van Reekum,

Robert van Reekum

Kunin-Lunenfeld Applied Research Unit Baycrest, Toronto, Ontario, Canada

Search for more papers by this author

Nicolaas P.L.G. Verhoeff,

Corresponding Author

Nicolaas P.L.G. Verhoeff

[email protected]
11-416-785-2500. ext. 2167 | Fax: 11-416-785-4230

Kunin-Lunenfeld Applied Research Unit Baycrest, Toronto, Ontario, Canada

Corresponding author. Tel.: 11-416-785-2500. ext. 2167; Fax: 11-416-785-4230.

E-mail address: [email protected]

Search for more papers by this author

Kie Honjo,

Kie Honjo

L.C. Campbell Cognitive Neurology Research Unit, Heart and Stroke Foundation Centre for Stroke Recovery, Section of Neurology, Department of Medicine, Sunnybrook Health Science Centre and University of Toronto, Toronto, Ontario, Canada

Kunin-Lunenfeld Applied Research Unit Baycrest, Toronto, Ontario, Canada

Search for more papers by this author

Robert van Reekum,

Robert van Reekum

Kunin-Lunenfeld Applied Research Unit Baycrest, Toronto, Ontario, Canada

Search for more papers by this author

Nicolaas P.L.G. Verhoeff,

Corresponding Author

Nicolaas P.L.G. Verhoeff

[email protected]
11-416-785-2500. ext. 2167 | Fax: 11-416-785-4230

Kunin-Lunenfeld Applied Research Unit Baycrest, Toronto, Ontario, Canada

Corresponding author. Tel.: 11-416-785-2500. ext. 2167; Fax: 11-416-785-4230.

E-mail address: [email protected]

Search for more papers by this author

First published: 01 July 2009

https://doi.org/10.1016/j.jalz.2008.12.001

Citations: 136

Read the full text

About

PDF

Tools

Share a link

Email
Facebook
Twitter
LinkedIn
Reddit
Wechat

Abstract

Infection with several important pathogens could constitute risk factors for cognitive impairment, dementia, and Alzheimer's disease (AD) in particular. This review summarizes the data related to infectious agents that appear to have a relationship with AD. Infections with herpes simplex virus type 1, picornavirus, Borna disease virus, Chlamydia pneumoniae, Helicobacter pylori, and spirochete were reported to contribute to the pathophysiology of AD or to cognitive changes. Based on these reports, it may be hypothesized that central nervous system or systemic infections may contribute to the pathogenesis or pathophysiology of AD, and chronic infection with several pathogens should be considered a risk factor for sporadic AD. If this hypothesis holds true, early intervention against infection may delay or even prevent the future development of AD.

References

[1]Alzheimer's Disease International. Media quick facts: the global impact of dementia. London: Alzheimer's Disease International; 1997–2007. Updated December 15, 2005; cited July 25, 2007. Available from: http://www.alz.co.uk/media/dementia.html.

Google Scholar
[2]Office of Science Policy Analysis. Economic studies program: disease-specific estimates of direct and indirect costs and NIH support. Fiscal year 2000 update. Bethesda, MD: National Institutes of Health. Updated June 2, 2000; cited July 25, 2007. Available from: http://ospp.od.nih.gov/ecostudies/COIreportweb.html.

Google Scholar
[3]M. Roth. The natural history of mental disorder in old age. J Ment Sci. 101: 1955; 281–301
10.1192/bjp.101.423.281
CASPubMedWeb of Science®Google Scholar
[4]J.C. de la Torre. Alzheimer disease as a vascular disorder: nosological evidence. Stroke. 33: 2002; 1152–1162
10.1161/01.STR.0000014421.15948.67
CASPubMedWeb of Science®Google Scholar
[5]P.B. Gorelick. Risk factors for vascular dementia and Alzheimer disease. Stroke. 35 (Suppl. 1): 2004; 2620–2622

Google Scholar
[6]J.F. Cleobury, G.R. Skinner, M.E. Thouless, P. Wildy. Association between psychopathic disorder and serum antibody to herpes simplex virus (type 1). Br Med J [Clin Res]. 1: 1971; 438–439
10.1136/bmj.1.5746.438
CASPubMedWeb of Science®Google Scholar
[7]E. Lycke, R. Norrby, B.E. Roos. A serological study on mentally ill patients with particular reference to the prevalence of herpes virus infections. Br J Psychiatry. 124: 1974; 273–279
10.1192/bjp.124.3.273
CASPubMedWeb of Science®Google Scholar
[8]L.W. Sequiera, L.C. Jennings, L.H. Carrasco, M.A. Lord, A. Curry, R.N. Sutton. Detection of herpes-simplex viral genome in brain tissue. Lancet. 2: 1979; 609–612
10.1016/S0140-6736(79)91667-2
CASPubMedWeb of Science®Google Scholar
[9]P.J. Middleton, M. Petric, M. Kozak, N.B. Rewcastle, D.R. McLachlan. Herpes-simplex viral genome and senile and presenile dementias of Alzheimer and Pick. Lancet. 1: 1980; 1038

Google Scholar
[10]B.G. Pogo, J. Casals, T.S. Elizan. A study of viral genomes and antigens in brains of patients with Alzheimer's disease. Brain. 110: 1987; 907–915
10.1093/brain/110.4.907
PubMedWeb of Science®Google Scholar
[11]B.G. Pogo, T.S. Elizan. Search for viral DNA sequences in Alzheimer brain tissue. Lancet. 1: 1985; 978–979
10.1016/S0140-6736(85)91743-X
PubMedWeb of Science®Google Scholar
[12]E.B. Renvoize, I.O. Awad, M.H. Hambling. A sero-epidemiological study of conventional infectious agents in Alzheimer's disease. Age Ageing. 16: 1987; 311–314
10.1093/ageing/16.5.311
CASPubMedWeb of Science®Google Scholar
[13]E.B. Renvoize, M.H. Hambling. Cytomegalovirus infection and Alzheimer's disease. Age Ageing. 13: 1984; 205–209
10.1093/ageing/13.4.205
CASPubMedWeb of Science®Google Scholar
[14]G.A. Jamieson, N.J. Maitland, G.K. Wilcock, J. Craske, R.F. Itzhaki. Latent herpes simplex virus type 1 in normal and Alzheimer's disease brains. J Med Virol. 33: 1991; 224–227
10.1002/jmv.1890330403
CASPubMedWeb of Science®Google Scholar
[15]G.A. Jamieson, N.J. Maitland, G.K. Wilcock, C.M. Yates, R.F. Itzhaki. Herpes simplex virus type 1 DNA is present in specific regions of brain from aged people with and without senile dementia of the Alzheimer type. J Pathol. 167: 1992; 365–368
10.1002/path.1711670403
CASPubMedWeb of Science®Google Scholar
[16]J. Miklossy. Alzheimer's disease—a spirochetosis? Neuroreport. 4: 1993; 841–848
10.1097/00001756-199307000-00002
CASPubMedWeb of Science®Google Scholar
[17]J. Miklossy, S. Kasas, R.C. Janzer, F. Ardizzoni, H. Van der Loos. Further ultrastructural evidence that spirochaetes may play a role in the aetiology of Alzheimer's disease. Neuroreport. 5: 1994; 1201–1204
10.1097/00001756-199406020-00010
CASPubMedWeb of Science®Google Scholar
[18]B.J. Balin, H.C. Gerard, E.J. Arking, D.M. Appelt, P.J. Branigan, J.T. Abrams, et al. Identification and localization of Chlamydia pneumoniae in the Alzheimer's brain. Med Microbiol Immunol (Berl). 187: 1998; 23–42
10.1007/s004300050071
CASPubMedWeb of Science®Google Scholar
[19]J. Kountouras, M. Tsolaki, E. Gavalas, M. Boziki, C. Zavos, P. Karatzoglou, et al. Relationship between Helicobacter pylori infection and Alzheimer disease. Neurology. 66: 2006; 938–940
10.1212/01.wnl.0000203644.68059.5f
CASPubMedWeb of Science®Google Scholar
[20]J. Miklossy, K. Khalili, L. Gern, R.L. Ericson, P. Darekar, L. Bolle, et al. Borrelia burgdorferi persists in the brain in chronic Lyme neuroborreliosis and may be associated with Alzheimer disease. J Alzheimers Dis. 6: 2004; 639–649
10.3233/JAD-2004-6608
PubMedWeb of Science®Google Scholar
[21]H. Akiyama, S. Barger, S. Barnum, B. Bradt, J. Bauer, G.M. Cole, et al. Inflammation and Alzheimer's disease. Neurobiol Aging. 21: 2000; 383–421
10.1016/S0197-4580(00)00124-X
CASPubMedWeb of Science®Google Scholar
[22]M. Mamelak. Alzheimer's disease, oxidative stress and gammahydroxybutyrate. Neurobiol Aging. 28: 2007; 1340–1360
10.1016/j.neurobiolaging.2006.06.008
CASPubMedWeb of Science®Google Scholar
[23]C.C. Stichel, H. Luebbert. Inflammatory processes in the aging mouse brain: participation of dendritic cells and T-cells. Neurobiol Aging. 28: 2007; 1507–1521
10.1016/j.neurobiolaging.2006.07.022
CASPubMedWeb of Science®Google Scholar
[24]W.R. Lin, R. Jennings, T.L. Smith, M.A. Wozniak, R.F. Itzhaki. Vaccination prevents latent HSV1 infection of mouse brain. Neurobiol Aging. 22: 2001; 699–703
10.1016/S0197-4580(01)00239-1
CASPubMedWeb of Science®Google Scholar
[25]M.A. Wozniak, S.J. Shipley, M. Combrinck, G.K. Wilcock, R.F. Itzhaki. Productive herpes simplex virus in brain of elderly normal subjects and Alzheimer's disease patients. J Med Virol. 75: 2005; 300–306
10.1002/jmv.20271
PubMedWeb of Science®Google Scholar
[26]Y. Becker. HSV-1 brain infection by the olfactory nerve route and virus latency and reactivation may cause learning and behavioral deficiencies and violence in children and adults: a point of view. Virus Genes. 10: 1995; 217–226
10.1007/BF01701811
CASPubMedWeb of Science®Google Scholar
[27]I. Boggian, E. Buzzacaro, A. Calistri, P. Calvi, A. Cavaggioni, C. Mucignat-Caretta, et al. Asymptomatic herpes simplex type 1 virus infection of the mouse brain. J Neurovirol. 6: 2000; 303–313
10.3109/13550280009030756
CASPubMedWeb of Science®Google Scholar
[28]L. Gordon, S. McQuaid, S.L. Cosby. Detection of herpes simplex virus (types 1 and 2) and human herpesvirus 6 DNA in human brain tissue by polymerase chain reaction. Clin Diagn Virol. 6: 1996; 33–40
10.1016/0928-0197(95)00203-0
CASPubMedWeb of Science®Google Scholar
[29]R.F. Itzhaki, W.R. Lin, D. Shang, G.K. Wilcock, B. Faragher, G.A. Jamieson. Herpes simplex virus type 1 in brain and risk of Alzheimer's disease. Lancet. 349: 1997; 241–244
10.1016/S0140-6736(96)10149-5
CASPubMedWeb of Science®Google Scholar
[30]W.R. Lin, M.A. Wozniak, R.J. Cooper, G.K. Wilcock, R.F. Itzhaki. Herpesviruses in brain and Alzheimer's disease. J Pathol. 197: 2002; 395–402
10.1002/path.1127
CASPubMedWeb of Science®Google Scholar
[31]U. Beffert, P. Bertrand, D. Champagne, S. Gauthier, J. Poirier. HSV-1 in brain and risk of Alzheimer's disease. Lancet. 351: 1998; 1330–1331
10.1016/S0140-6736(05)79057-7
CASPubMedWeb of Science®Google Scholar
[32]P. Bertrand, D. Guillaume, K. Hellauer, D. Dea, J. Lindsay, S. Kogan, et al. Distribution of herpes simplex virus type 1 DNA in selected areas of normal and Alzheimer's disease brains: a PCR study. Neurodegeneration. 2: 1993; 201–208

Google Scholar
[33]T. Valyi-Nagy, S.J. Olson, K. Valyi-Nagy, T.J. Montine, T.S. Dermody. Herpes simplex virus type 1 latency in the murine nervous system is associated with oxidative damage to neurons. Virology. 278: 2000; 309–321
10.1006/viro.2000.0678
CASPubMedWeb of Science®Google Scholar
[34]M.A. Wozniak, R.F. Itzhaki, S.J. Shipley, C.B. Dobson. Herpes simplex virus infection causes cellular beta-amyloid accumulation and secretase upregulation. Neurosci Lett. 429: 2007; 95–100
10.1016/j.neulet.2007.09.077
CASPubMedWeb of Science®Google Scholar
[35]F.J. Denaro, P. Staub, J. Colmer, D.M. Freed. Coexistence of Alzheimer disease neuropathology with herpes simplex encephalitis. Cell Mol Biol (Noisy-le-Grand). 49: 2003; 1233–1240

Google Scholar
[36]E. Corder, L. Lannfelt, M. Mulder. Apolipoprotein E and herpes simplex virus 1 in Alzheimer's disease. Lancet. 352: 1998; 1312–1313
10.1016/S0140-6736(05)70525-0
CASPubMedWeb of Science®Google Scholar
[37]S. Itabashi, H. Arai, T. Matsui, S. Higuchi, H. Sasaki. Herpes simplex virus and risk of Alzheimer's disease. Lancet. 349: 1997; 1102
10.1016/S0140-6736(05)62325-2
CASPubMedWeb of Science®Google Scholar
[38]R.F. Itzhaki, W.R. Lin, G.K. Wilcock, B. Faragher. HSV-1 and risk of Alzheimer's disease. Lancet. 352: 1998; 238
10.1016/S0140-6736(05)77844-2
CASPubMedWeb of Science®Google Scholar
[39]R.F. Itzhaki, M.A. Wozniak. Herpes simplex virus type 1, apolipoprotein E, and cholesterol: a dangerous liaison in Alzheimer's disease and other disorders. Prog Lipid Res. 45: 2006; 73–90
10.1016/j.plipres.2005.11.003
CASPubMedWeb of Science®Google Scholar
[40]H. Isoniemi, O. Tenovuo, R. Portin, L. Himanen, V. Kairisto. Outcome of traumatic brain injury after three decades—relationship to ApoE genotype. J Neurotrauma. 23: 2006; 1600–1608
10.1089/neu.2006.23.1600
PubMedWeb of Science®Google Scholar
[41]E.H. Corder, K. Robertson, L. Lannfelt, N. Bogdanovic, G. Eggertsen, J. Wilkins, et al. HIV-infected subjects with the E4 allele for APOE have excess dementia and peripheral neuropathy. Nat Med. 4: 1998; 1182–1184
10.1038/2677
CASPubMedWeb of Science®Google Scholar
[42]A.J. Slooter, C.M. van Duijn. Genetic epidemiology of Alzheimer disease. Epidemiol Rev. 19: 1997; 107–119
10.1093/oxfordjournals.epirev.a017933
CASPubMedWeb of Science®Google Scholar
[43]M. Oshima, H. Azuma, T. Suzutani, H. Ikeda, A. Okuno. Direct and mononuclear cell mediated effects on interleukin 6 production by glioma cells in infection with herpes simplex virus type 1. J Med Virol. 63: 2001; 252–258
10.1002/1096-9071(200103)63:3<252::AID-JMV1009>3.0.CO;2-E
CASPubMedWeb of Science®Google Scholar
[44]J.D. Luterman, V. Haroutunian, S. Yemul, L. Ho, D. Purohit, P.S. Aisen, et al. Cytokine gene expression as a function of the clinical progression of Alzheimer disease dementia. Arch Neurol. 57: 2000; 1153–1160
10.1001/archneur.57.8.1153
CASPubMedWeb of Science®Google Scholar
[45]L.M. Huang, C.Y. Lee, P.I. Lee, J.M. Chen, P.J. Wang. Meningitis caused by human herpesvirus-6. Arch Dis Child. 66: 1991; 1443–1444
10.1136/adc.66.12.1443
CASPubMedWeb of Science®Google Scholar
[46]J.A. McCullers, F.D. Lakeman, R.J. Whitley. Human herpesvirus 6 is associated with focal encephalitis. Clin Infect Dis. 21: 1995; 571–576
10.1093/clinids/21.3.571
CASPubMedWeb of Science®Google Scholar
[47]M. Luppi, P. Barozzi, A. Maiorana, R. Marasca, G. Torelli. Human herpesvirus 6 infection in normal human brain tissue. J Infect Dis. 169: 1994; 943–944
10.1093/infdis/169.4.943
CASPubMedWeb of Science®Google Scholar
[48]H.B. Qavi. Possible role of HHV-6 in the enhanced severity of HSV-1 keratitis. In Vivo. 13: 1999; 427–432

CASPubMedWeb of Science®Google Scholar
[49]W.R. Lin, I. Casas, G.K. Wilcock, R.F. Itzhaki. Neurotropic viruses and Alzheimer's disease: a search for Varicella zoster virus DNA by the polymerase chain reaction. J Neurol Neurosurg Psychiatry. 62: 1997; 586–589
10.1136/jnnp.62.6.586
CASPubMedWeb of Science®Google Scholar
[50]S.D. Kittur, J.H. Hoh, C.H. Kawas, G.S. Hayward, H. Endo, W.H. Adler. A molecular hybridization study for the presence of herpes simplex, cytomegalovirus and Epstein-Barr virus in brain and blood of Alzheimer's disease patients. Arch Gerontol Geriatr. 15: 1992; 35–41
10.1016/0167-4943(92)90038-6
Google Scholar
[51]M.A. Wozniak, S.J. Shipley, C.B. Dobson, S.P. Parker, F.T. Scott, M. Leedham-Green, et al. Does apolipoprotein E determine outcome of infection by Varicella zoster virus and by Epstein Barr virus? Eur J Hum Genet. 15: 2007; 672–678
10.1038/sj.ejhg.5201812
CASPubMedWeb of Science®Google Scholar
[52]A. Volpi. Epstein-Barr virus and human herpesvirus type 8 infections of the central nervous system. Herpes. 11 (Suppl. 2): 2004; 120A–127A

PubMedGoogle Scholar
[53]R. Feuer, I. Mena, R.R. Pagarigan, S. Harkins, D.E. Hassett, J.L. Whitton. Coxsackievirus B3 and the neonatal CNS: the roles of stem cells, developing neurons, and apoptosis in infection, viral dissemination, and disease. Am J Pathol. 163: 2003; 1379–1393
10.1016/S0002-9440(10)63496-7
CASPubMedWeb of Science®Google Scholar
[54]W. Su, A. Ueno-Yamanouchi, K. Uetsuka, H. Nakayama, K. Doi. Age-related changes in susceptibility of rat brain slice cultures including hippocampus to encephalomyocarditis virus. Int J Exp Pathol. 80: 1999; 349–355
10.1046/j.1365-2613.1999.00133.x
PubMedWeb of Science®Google Scholar
[55]E.J. Buenz, M. Rodriguez, C.L. Howe. Disrupted spatial memory is a consequence of picornavirus infection. Neurobiol Dis. 24: 2006; 266–273
10.1016/j.nbd.2006.07.003
PubMedWeb of Science®Google Scholar
[56]J.L. Price, A.I. Ko, M.J. Wade, S.K. Tsou, D.W. McKeel, J.C. Morris. Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Arch Neurol. 58: 2001; 1395–1402
10.1001/archneur.58.9.1395
CASPubMedWeb of Science®Google Scholar
[57]R.C. Petersen, J.E. Parisi, D.W. Dickson, K.A. Johnson, D.S. Knopman, B.F. Boeve, et al. Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol. 63: 2006; 665–672
10.1001/archneur.63.5.665
PubMedWeb of Science®Google Scholar
[58]L. Bode, W. Zimmermann, R. Ferszt, F. Steinbach, H. Ludwig. Borna disease virus genome transcribed and expressed in psychiatric patients. Nat Med. 1: 1995; 232–236
10.1038/nm0395-232
CASPubMedWeb of Science®Google Scholar
[59]R. Rott, S. Herzog, B. Fleischer, A. Winokur, J. Amsterdam, W. Dyson, et al. Detection of serum antibodies to Borna disease virus in patients with psychiatric disorders. Science. 228: 1985; 755–756
10.1126/science.3922055
CASPubMedWeb of Science®Google Scholar
[60]P. Staeheli, C. Sauder, J. Hausmann, F. Ehrensperger, M. Schwemmle. Epidemiology of Borna disease virus. J Gen Virol. 81: 2000; 2123–2135
10.1099/0022-1317-81-9-2123
CASPubMedWeb of Science®Google Scholar
[61]W. Dittrich, L. Bode, H. Ludwig, M. Kao, K. Schneider. Learning deficiencies in Borna disease virus-infected but clinically healthy rats. Biol Psychiatry. 26: 1989; 818–828
10.1016/0006-3223(89)90122-4
CASPubMedWeb of Science®Google Scholar
[62]C. Sauder, D.P. Wolfer, H.P. Lipp, P. Staeheli, J. Hausmann. Learning deficits in mice with persistent Borna disease virus infection of the CNS associated with elevated chemokine expression. Behav Brain Res. 120: 2001; 189–201
10.1016/S0166-4328(00)00370-3
CASPubMedWeb of Science®Google Scholar
[63]T. Stahl, C. Reimers, R. Johne, R. Schliebs, J. Seeger. Viral-induced inflammation is accompanied by beta-amyloid plaque reduction in brains of amyloid precursor protein transgenic Tg2576 mice. Eur J Neurosci. 24: 2006; 1923–1934
10.1111/j.1460-9568.2006.05069.x
CASPubMedWeb of Science®Google Scholar
[64]M. Pfeifer, S. Boncristiano, L. Bondolfi, A. Stalder, T. Deller, M. Staufenbiel, et al. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science. 298: 2002; 1379
10.1126/science.1078259
CASPubMedWeb of Science®Google Scholar
[65]W.M. Wojtowicz, M. Farzan, J.L. Joyal, K. Carter, G.J. Babcock, D.I. Israel, et al. Stimulation of enveloped virus infection by beta-amyloid fibrils. J Biol Chem. 277: 2002; 35019–35024
10.1074/jbc.M203518200
CASPubMedWeb of Science®Google Scholar
[66]O. Heinonen, S. Syrjanen, R. Mantyjarvi, K. Syrjanen, P. Riekkinen. JC virus infection and Alzheimer's disease: reappraisal of an in situ hybridization approach. Ann Neurol. 31: 1992; 439–441
10.1002/ana.410310415
CASPubMedWeb of Science®Google Scholar
[67]M.M. Esiri, S.C. Biddolph, C.S. Morris. Prevalence of Alzheimer plaques in AIDS. J Neurol Neurosurg Psychiatry. 65: 1998; 29–33
10.1136/jnnp.65.1.29
CASPubMedWeb of Science®Google Scholar
[68]H.C. Rempel, L. Pulliam. HIV-1 Tat inhibits neprilysin and elevates amyloid beta. AIDS. 19: 2005; 127–135
10.1097/00002030-200501280-00004
CASPubMedWeb of Science®Google Scholar
[69]D.A. Green, E. Masliah, H.V. Vinters, P. Beizai, D.J. Moore, C.L. Achim. Brain deposition of beta-amyloid is a common pathologic feature in HIV positive patients. AIDS. 19: 2005; 407–411
10.1097/01.aids.0000161770.06158.5c
CASPubMedWeb of Science®Google Scholar
[70]K. Bachmaier, N. Neu, L.M. de la Maza, S. Pal, A. Hessel, J.M. Penninger. Chlamydia infections and heart disease linked through antigenic mimicry. Science. 283: 1999; 1335–1339
10.1126/science.283.5406.1335
CASPubMedWeb of Science®Google Scholar
[71]M.S. Elkind, M.L. Tondella, D.R. Feikin, B.S. Fields, S. Homma, M.R. Di Tullio. Seropositivity to Chlamydia pneumoniae is associated with risk of first ischemic stroke. Stroke. 37: 2006; 790–795
10.1161/01.STR.0000202624.89869.e9
CASPubMedWeb of Science®Google Scholar
[72]J.T. Grayston, M.B. Aldous, A. Easton, S.P. Wang, C.C. Kuo, L.A. Campbell, et al. Evidence that Chlamydia pneumoniae causes pneumonia and bronchitis. J Infect Dis. 168: 1993; 1231–1235
10.1093/infdis/168.5.1231
CASPubMedWeb of Science®Google Scholar
[73]M.L. Wimmer, R. Sandmann-Strupp, P. Saikku, R.L. Haberl. Association of chlamydial infection with cerebrovascular disease. Stroke. 27: 1996; 2207–2210
10.1161/01.STR.27.12.2207
PubMedWeb of Science®Google Scholar
[74]L. Capron. Chlamydia in coronary plaques—hidden culprit or harmless hobo? Nat Med. 2: 1996; 856–857
10.1038/nm0896-856
CASPubMedWeb of Science®Google Scholar
[75]M. Maass, C. Bartels, P.M. Engel, U. Mamat, H.H. Sievers. Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease. J Am Coll Cardiol. 31: 1998; 827–832
10.1016/S0735-1097(98)00016-3
CASPubMedWeb of Science®Google Scholar
[76]F.R. Stassen, T. Vainas, C.A. Bruggeman. Infection and atherosclerosis. An alternative view on an outdated hypothesis. Pharmacol Rep. 60: 2008; 85–92

CASPubMedWeb of Science®Google Scholar
[77]H.C. Gerard, U. Dreses-Werringloer, K.S. Wildt, S. Deka, C. Oszust, B.J. Balin, et al. Chlamydophila (Chlamydia) pneumoniae in the Alzheimer's brain. FEMS Immunol Med Microbiol. 48: 2006; 355–366
10.1111/j.1574-695X.2006.00154.x
CASPubMedWeb of Science®Google Scholar
[78]H.C. Gerard, K.L. Wildt, J.A. Whittum-Hudson, Z. Lai, J. Ager, A.P. Hudson. The load of Chlamydia pneumoniae in the Alzheimer's brain varies with APOE genotype. Microb Pathog. 39: 2005; 19–26
10.1016/j.micpath.2005.05.002
CASPubMedWeb of Science®Google Scholar
[79]J. Gieffers, E. Reusche, W. Solbach, M. Maass. Failure to detect Chlamydia pneumoniae in brain sections of Alzheimer's disease patients. J Clin Microbiol. 38: 2000; 881–882

CASPubMedWeb of Science®Google Scholar
[80]D. Nochlin, C.M. Shaw, L.A. Campbell, C.C. Kuo. Failure to detect Chlamydia pneumoniae in brain tissues of Alzheimer's disease. Neurology. 53: 1999; 1888
10.1212/WNL.53.8.1888-a
CASPubMedWeb of Science®Google Scholar
[81]C.S. Little, C.J. Hammond, A. MacIntyre, B.J. Balin, D.M. Appelt. Chlamydia pneumoniae induces Alzheimer-like amyloid plaques in brains of BALB/c mice. Neurobiol Aging. 25: 2004; 419–429
10.1016/S0197-4580(03)00127-1
CASPubMedWeb of Science®Google Scholar
[82]G. Forloni, L. Colombo, L. Girola, F. Tagliavini, M. Salmona. Anti-amyloidogenic activity of tetracyclines: studies in vitro. FEBS Lett. 487: 2001; 404–407
10.1016/S0014-5793(00)02380-2
CASPubMedWeb of Science®Google Scholar
[83]T. Tomiyama, A. Shoji, K. Kataoka, Y. Suwa, S. Asano, H. Kaneko, et al. Inhibition of amyloid beta protein aggregation and neurotoxicity by rifampicin. Its possible function as a hydroxyl radical scavenger. J Biol Chem. 271: 1996; 6839–6844
10.1074/jbc.271.12.6839
CASPubMedWeb of Science®Google Scholar
[84]M.B. Loeb, D.W. Molloy, M. Smieja, T. Standish, C.H. Goldsmith, J. Mahony, et al. A randomized, controlled trial of doxycycline and rifampin for patients with Alzheimer's disease. J Am Geriatr Soc. 52: 2004; 381–387
10.1111/j.1532-5415.2004.52109.x
PubMedWeb of Science®Google Scholar
[85]N. Verhoeff. Do NSAIDs reduce the risk of developing AD? CAGP Bull. 10: 2003; 14–15

Google Scholar
[86]B.J. Marshall, J.R. Warren. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1: 1984; 1311–1315
10.1016/S0140-6736(84)91816-6
CASPubMedWeb of Science®Google Scholar
[87]C.W. Howden. Clinical expressions of Helicobacter pylori infection. Am J Med. 100 (Suppl.): 1996; 27S–32S

Google Scholar
[88]J. Kountouras, G. Deretzi, C. Zavos, P. Karatzoglou, L. Touloumis, T. Nicolaides, et al. Association between Helicobacter pylori infection and acute inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol. 12: 2005; 139–143
10.1111/j.1468-1331.2004.00977.x
CASPubMedWeb of Science®Google Scholar
[89]J. Kountouras, N. Mylopoulos, D. Chatzopoulos, C. Zavos, P. Boura, A.G. Konstas, et al. Eradication of Helicobacter pylori may be beneficial in the management of chronic open-angle glaucoma. Arch Intern Med. 162: 2002; 1237–1244
10.1001/archinte.162.11.1237
PubMedWeb of Science®Google Scholar
[90]M. Malaguarnera, R. Bella, G. Alagona, R. Ferri, A. Carnemolla, G. Pennisi. Helicobacter pylori and Alzheimer's disease: a possible link. Eur J Intern Med. 15: 2004; 381–386
10.1016/j.ejim.2004.05.008
PubMedGoogle Scholar
[91]A. McCaddon, G. Davies, P. Hudson. Nutritionally independent B12 deficiency and Alzheimer disease. Arch Neurol. 57: 2000; 607–608
10.1001/archneur.57.4.607
CASPubMedWeb of Science®Google Scholar
[92]S. Seshadri, A. Beiser, J. Selhub, P.F. Jacques, I.H. Rosenberg, R.B. D'Agostino, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med. 346: 2002; 476–483
10.1056/NEJMoa011613
CASPubMedWeb of Science®Google Scholar
[93]A.J. Grau, F. Buggle, C. Lichy, T. Brandt, H. Becher, J. Rudi. Helicobacter pylori infection as an independent risk factor for cerebral ischemia of atherothrombotic origin. J Neurol Sci. 186: 2001; 1–5
10.1016/S0022-510X(01)00507-X
CASPubMedWeb of Science®Google Scholar
[94]P.U. Heuschmann, D. Neureiter, M. Gesslein, B. Craiovan, M. Maass, G. Faller, et al. Association between infection with Helicobacter pylori and Chlamydia pneumoniae and risk of ischemic stroke subtypes: results from a population-based case-control study. Stroke. 32: 2001; 2253–2258
10.1161/hs1001.097096
CASPubMedWeb of Science®Google Scholar
[95]H.S. Markus, M.A. Mendall. Helicobacter pylori infection: a risk factor for ischaemic cerebrovascular disease and carotid atheroma. J Neurol Neurosurg Psychiatry. 64: 1998; 104–107
10.1136/jnnp.64.1.104
CASPubMedWeb of Science®Google Scholar
[96]R. Schmidt, H. Schmidt, J.D. Curb, K. Masaki, L.R. White, L.J. Launer. Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Ann Neurol. 52: 2002; 168–174
10.1002/ana.10265
CASPubMedWeb of Science®Google Scholar
[97]A.U. Bayer, F. Ferrari, C. Erb. High occurrence rate of glaucoma among patients with Alzheimer's disease. Eur Neurol. 47: 2002; 165–168
10.1159/000047976
CASPubMedWeb of Science®Google Scholar
[98]H. Tamura, H. Kawakami, T. Kanamoto, T. Kato, T. Yokoyama, K. Sasaki, et al. High frequency of open-angle glaucoma in Japanese patients with Alzheimer's disease. J Neurol Sci. 246: 2006; 79–83
10.1016/j.jns.2006.02.009
PubMedWeb of Science®Google Scholar
[99]T. Sugiyama, K. Utsunomiya, H. Ota, Y. Ogura, I. Narabayashi, T. Ikeda. Comparative study of cerebral blood flow in patients with normal-tension glaucoma and control subjects. Am J Ophthalmol. 141: 2006; 394–396
10.1016/j.ajo.2005.08.037
PubMedWeb of Science®Google Scholar
[100]G.R. Riviere, K.H. Riviere, K.S. Smith. Molecular and immunological evidence of oral treponema in the human brain and their association with Alzheimer's disease. Oral Microbiol Immunol. 17: 2002; 113–118
10.1046/j.0902-0055.2001.00100.x
CASPubMedWeb of Science®Google Scholar
[101]J. Miklossy, A. Kis, A. Radenovic, L. Miller, L. Forro, R. Martins, et al. Beta-amyloid deposition and Alzheimer's type changes induced by Borrelia spirochetes. Neurobiol Aging. 27: 2006; 228–236
10.1016/j.neurobiolaging.2005.01.018
CASPubMedWeb of Science®Google Scholar
[102]R. McLaughlin, N.M. Kin, M.F. Chen, N.P. Nair, E.C. Chan. Alzheimer's disease may not be a spirochetosis. Neuroreport. 10: 1999; 1489–1491
10.1097/00001756-199905140-00018
CASPubMedWeb of Science®Google Scholar
[103]R.F. Itzhaki, M.A. Wozniak, D.M. Appelt, B.J. Balin. Infiltration of the brain by pathogens causes Alzheimer's disease. Neurobiol Aging. 25: 2004; 619–627
10.1016/j.neurobiolaging.2003.12.021
CASPubMedWeb of Science®Google Scholar
[104]S.L. Tyas, J. Manfreda, L.A. Strain, P.R. Montgomery. Risk factors for Alzheimer's disease: a population-based, longitudinal study in Manitoba, Canada. Int J Epidemiol. 30: 2001; 590–597
10.1093/ije/30.3.590
CASPubMedWeb of Science®Google Scholar
[105]R. Verreault, D. Laurin, J. Lindsay, G. De Serres. Past exposure to vaccines and subsequent risk of Alzheimer's disease. Can Med Assoc J. 165: 2001; 1495–1498

CASPubMedWeb of Science®Google Scholar
[106]A.B. Hill. The environment and disease: association or causation? Proc R Soc Med. 58: 1965; 295–300
10.1177/003591576505800503
CASPubMedWeb of Science®Google Scholar
[107]R. van Reekum, D.L. Streiner, D.K. Conn. Applying Bradford Hill's criteria for causation to neuropsychiatry: challenges and opportunities. J Neuropsychiatry Clin Neurosci. 13: 2001; 318–325
10.1176/jnp.13.3.318
PubMedWeb of Science®Google Scholar
[108]R.F. Itzhaki, M. Wozniak, C. Dobson, W.R. Lin. ApoE-viral interactions. Nat Med. 4: 1998; 1344

Google Scholar
[109]J.S. Burgos, C. Ramirez, I. Sastre, F. Valdivieso. Effect of apolipoprotein E on the cerebral load of latent herpes simplex virus type 1 DNA. J Virol. 80: 2006; 5383–5387
10.1128/JVI.00006-06
CASPubMedWeb of Science®Google Scholar
[110]D. Pratico. Peripheral biomarkers of oxidative damage in Alzheimer's disease: the road ahead. Neurobiol Aging. 26: 2005; 581–583
10.1016/j.neurobiolaging.2004.09.020
CASPubMedWeb of Science®Google Scholar
[111]A.R. Kamer, R.G. Craig, A.P. Dasanayake, M. Brys, L. Glodzik-Sobanska, M.J. de Leon. Inflammation and Alzheimer's disease: possible role of periodontal diseases. Alzheimers Dement. 4: 2008; 242–250
10.1016/j.jalz.2007.08.004
CASPubMedWeb of Science®Google Scholar
[112]Z.S. Tan, A.S. Beiser, R.S. Vasan, R. Roubenoff, C.A. Dinarello, T.B. Harris, et al. Inflammatory markers and the risk of Alzheimer disease: the Framingham Study. Neurology. 68: 2007; 1902–1908
10.1212/01.wnl.0000263217.36439.da
CASPubMedWeb of Science®Google Scholar
[113]S.T. DeKosky, M.D. Ikonomovic, X. Wang, M. Farlow, S. Wisniewski, O.L. Lopez, et al. Plasma and cerebrospinal fluid alpha1-antichymotrypsin levels in Alzheimer's disease: correlation with cognitive impairment. Ann Neurol. 53: 2003; 81–90
10.1002/ana.10414
CASPubMedWeb of Science®Google Scholar
[114]D.L. Simmons, R.M. Botting, T. Hla. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev. 56: 2004; 387–437
10.1124/pr.56.3.3
CASPubMedWeb of Science®Google Scholar
[115]J.H. Jang, Y.J. Surh. Beta-amyloid-induced apoptosis is associated with cyclooxygenase-2 up-regulation via the mitogen-activated protein kinase-NF-kappaB signaling pathway. Free Radic Biol Med. 38: 2005; 1604–1613
10.1016/j.freeradbiomed.2005.02.023
CASPubMedWeb of Science®Google Scholar
[116]B.M. Gebhardt, E.D. Varnell, H.E. Kaufman. Inhibition of cyclooxygenase 2 synthesis suppresses herpes simplex virus type 1 reactivation. J Ocul Pharmacol Ther. 21: 2005; 114–120
10.1089/jop.2005.21.114
CASPubMedWeb of Science®Google Scholar
[117]H. Soininen, C. West, J. Robbins, L. Niculescu. Long-term efficacy and safety of celecoxib in Alzheimer's disease. Dement Geriatr Cogn Disord. 23: 2007; 8–21
10.1159/000096588
CASPubMedWeb of Science®Google Scholar
[118]M.R. Farlow, Y. He, S. Tekin, J. Xu, R. Lane, H.C. Charles. Impact of APOE in mild cognitive impairment. Neurology. 63: 2004; 1898–1901
10.1212/01.WNL.0000144279.21502.B7
CASPubMedWeb of Science®Google Scholar

Citing Literature

Volume5, Issue4

July 2009

Pages 348-360

Download PDF